Abstract 84P
Background
Macrophages represent the main infiltrating immune subset in most cancer types and tumor-associated macrophages (TAMs) sustain tumor growth, promote invasion and mediate immune suppression. Interestingly, a population of lipid-loaded macrophages has been recently identified in prostate cancer, colon cancer and melanoma. However, the mechanisms that drive lipid accumulation in macrophages and the functional impact of lipid-loading still need to be uncovered.
Methods
We profiled the cancer immune infiltrate in a murine model of melanoma and we performed bulk RNA sequencing of lipid-loaded macrophages to investigate pathways involved in lipid accumulation. We applied in vitro assays to dissect the interplay between macrophages and melanoma cells and we took advantage of immunofluorescence analysis to study the mechanisms responsible for lipid accumulation in tumor-conditioned macrophages.
Results
We confirmed that lipid accumulation is a feature of TAMs in melanoma and we observed that lipid-loaded macrophages express markers of immunosuppression, including arginase and PD-L1. Importantly, the abundance of lipid-loaded macrophages correlates with tumor size, suggesting their support to tumor progression. In vitro, cancer cells shift the polarization of macrophages toward a pro-tumoral state and augment their capability to accumulate lipid droplets when triggered with lipid species. In addition, autophagic flux resulted impaired in macrophages exposed to tumor cells, suggesting defective autophagy as a potential mechanism responsible for lipid accumulation. In the end, we observed that transcription factor EB (TFEB) is deregulated in tumor-conditioned macrophages, indicating a role of TFEB in promoting autophagy deficiency and lipid accumulation in TAMs.
Conclusions
Here we show that TAMs in melanoma accumulate lipids and acquire pro-tumorigenic and immunosuppressive features. Additionally, the inactivation of transcription factor EB promotes a defective autophagic machinery that could be relevant in lipid accumulation in TAMs. In this context, we believe that TFEB activation may prevent lipid accumulation thus potentially improving efficacy of current available immunotherapies and therefore representing a promising opportunity for cancer therapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Fondazione AIRC per la Ricerca sul Cancro.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract